Drug intelligence / Profile preview

BIM-38131

Development stage: Preclinical
Lead developer: AbbVie
Modality: Small Molecules

Overview

BIM-38131 is a ghrelin receptor agonist developed by Ipsen as a preclinical candidate for treating gastrointestinal motility disorders and cachexia associated with conditions like cancer. It acts by mimicking the action of ghrelin, a hormone that stimulates appetite and gut motility via activation of the growth hormone secretagogue receptor (GHSR). The program was licensed to Rhythm Pharmaceuticals, highlighting its potential in addressing hypomotility and wasting syndromes.[3]

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on BIM-38131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIM-38131.

Explore the full profile